Navigation Links
Bionovo Receives Positive Guidance from FDA on Menerba®
Date:8/30/2010

es, prior to clinical dosing, Bionovo will complete a 28 day bioequivalence study in rats. The agency also requested that Bionovo provide selected batch records for review. It is important to remember that Menerba was effective in Phase 2 and showed no signs of safety concerns in human or animal studies to date."

"With the CMC preparations complete, we can now turn our attention to finalizing the communication on the clinical trial design with the FDA in the coming weeks," said Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer. "We expect to be able to initiate pivotal trials by year end."

Previously, the Company received final guidance from the European Medicines Agency (EMA) in order to advance Menerba to Phase 3 clinical trials in Europe. The EMA guidance defines the clinical and regulatory pathway to a European marketing authorization for Menerba. With this EMA guidance, and the FDA guidance, the Company is now preparing for pivotal clinical trials in the U.S. and Europe.

About Menerba

Menerba is an oral, botanical-derived drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. Menerba is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to the products currently on the market, which have been shown to increase the risk for breast and uterine cancers. Clinical tests conducted thus far, following the specific guidance of the FDA, have indicated that Menerba is effective and safe.

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Bionovo Announces Reverse Stock Split
2. Bionovo Announces Publication Describing Menerbas Effect on Neural Pathways Related to Temperature Regulation
3. Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe
4. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2010 Financial Results on Wednesday, August 4, 2010
5. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
6. Bionovo Announces 2009 Highlights and Year-End Financial Results
7. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
8. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
9. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
10. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
11. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... named the 2013 Life Science Firm of the Year by ... Vanda was honored at the TCM,s 25 th Annual ... Maryland.  The Tech Awards Celebration recognizes the leaders and innovators ... Maryland and the surrounding regions. ...
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... Care Conference in Boston.   The live presentation ... Time / 8:20 a.m. Pacific Time.  The presentation will be ... http://www.neurocrine.com . If you are unable ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... (CRL) has invested in a low-dose, state-of-the-art CT machine ... Minnesota.  This advanced diagnostic system will help physicians reach ... care with a radiation dose up to 40% lower ... "The addition of the GE Healthcare Brightspeed Elite CT ...
... ECRI Institute ®, an independent ... improving patient care, today announces the launch of its ... to ECRI Institute,s SELECTplus™ healthcare technology advisory service. The ... intelligence to help hospitals and health systems select and ...
Cached Medicine Technology:Consulting Radiologists, Ltd. Announces Addition of a Low Dose Advanced Computed Tomography (CT) System 2ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions 2ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions 3
(Date:5/23/2013)... Science published an article about bexarotene as a ... starting point for further Alzheimer,s research. The research group ... and KU Leuven in collaboration with the group ... at Janssen Pharmaceutica, Beerse, also tested this candidate drug ... different, as were those of two American study groups. ...
(Date:5/23/2013)... being dragged to its destruction inside a cell, ... signals that thwart the development of tumor-suppressing microRNAs ... early online publication at Nature . , ... tumors, the epidermal growth factor receptor (EGFR) gums ... led by scientists at The University of Texas ...
(Date:5/23/2013)... 23, 2013 The Rottenstein Law Group ... has created the Tylenol Lawsuit Information Center at ... users and those who are considering filing lawsuits. ... potentially cause severe liver damage, according to a 2009 ... In the “safety communication,” the FDA warned consumers against ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
(Date:5/23/2013)... Jeanne Ettelson, president of Beyond OCD , ... free OCD support group in Chicago. Launched in ... the group is lead by psychologists who specialize in ... group participants to learn accurate information about OCD, Cognitive ... in Beyond OCD’s support group benefit from being ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2
... by youngsters with the disease , THURSDAY, July 2 (HealthDay ... to be overweight than those without the disease, increasing their ... is from a major study that explored the weight problems ... common form of the disease that usually shows up in ...
... the launch of (RED)ZONES at the first U2 360 Degrees concert ... rapturous sold out crowd of 90,000 fans. , , ... will be present throughout the U2 tour. The tickets for ... the ticket sales going to the Global Fund to help fund ...
... reports of DEA intervention are accurate, Michael Jackson,s doctors will ... won,t end there. The pharmacists who filled Mr. Jackson,s prescriptions ... name is associated with any of Jackson,s prescriptions," said attorney ... won full federal jury acquittal at trial on a 10 ...
... Cardinal Health today announced that Bruce L. Downey will ... of the planned spinoff of CareFusion Corporation, replacing John B. ... after 22 years of service to the company as a ... chairman and chief executive officer of Barr Pharmaceuticals, Inc. and ...
... the advisory committee,s recommendations to the U.S. Food and Drug Administration (FDA) ... physician leaders from the American Academy of Pain Medicine ... The American Academy of Pain Medicine ... specialty of Pain Medicine, supports the safe and responsible, ...
... the pipeline, could plug a Percocet-Vicodin gap, experts say, , ... Percocet and Vicodin, which a U.S. health advisory panel has ... medical experts contend. , The reason, they say, is that ... Administration advisory panel made its recommendation Tuesday. It followed the ...
Cached Medicine News:Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3Health News:DEA Will Play Hardball in Investigating Michael Jackson's Doctors 2Health News:Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years 2Health News:Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen 2Health News:If 2 Painkillers Are Banned, What Next? 2Health News:If 2 Painkillers Are Banned, What Next? 3Health News:If 2 Painkillers Are Banned, What Next? 4
40-well gradient cycler...
... a high quality, compact thermal cycler. In addition ... Mastercycler personal offers first-rate operational flexibility. Its universal ... x 0.2 ml tubes, 16 x 0.5 ml ... grid format. Like the Mastercycler and the Mastercycler ...
... instrument and custom filter wheels with ... The standard filter set includes: FAM/SYBR ... Red (585nm-610nm), Cy5 (635nm-665nm) and Cy3 ... Mx3005P analysis software, Beacon Designer oligo ...
... The system includes: Mx3005P instrument and ... of five (5) filters. The standard ... (492nm-516nm), HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), ... included: desktop computer, Mx3005P analysis software, ...
Medicine Products: